Molecular targets related to inflammation and insulin resistance and potential interventions

Journal of Biomedicine and Biotechnology

Volumn 2012, Issue , 2012, Pages

  Hirabara, Sandro M ^a   Gorjão, Renata ^a   Vinolo, Marco A ^c   Rodrigues, Alice C ^b   Nachbar, Renato T ^b   Curi, Rui ^b  

^a UNIVERSIDADE CRUZEIRO DO SUL   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; HISTONE DEACETYLASE; INSULIN RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 6; NCK PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE PHOSPHATASE SHP; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; INSULIN;

ADIPOSE TISSUE; BIOTECHNOLOGY; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CELL SURVIVAL; CYTOKINE PRODUCTION; ENVIRONMENTAL STRESS; GENE EXPRESSION; GLUCOSE TRANSPORT; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; ANIMAL; IMMUNOLOGY; METHODOLOGY; MOLECULARLY TARGETED THERAPY;

ANIMALS; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; MOLECULAR TARGETED THERAPY;

EID: 84871836418     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2012/379024     Document Type: Review

References (178)

1. Sun X. J., Rothenberg P., Kahn C. R., Backer J. M., Araki E., Wilden P. A., Cahill D. A., Goldstein B. J., White M. F., Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991 352 6330 73 77 2-s2.0-0025813375 10.1038/352073a0 (Pubitemid 21896701)
2. Burks D. J., White M. F., IRS proteins and beta-cell function. Diabetes 2001 50 S140 S145 2-s2.0-0035260665
3. Durmuş Tekir S., Ümit P., Eren Toku A., Ülgen K. O., Reconstruction of protein-protein interaction network of insulin signaling in Homo sapiens. Journal of Biomedicine and Biotechnology 2010 2010 7 690925 10.1155/2010/690925 2-s2.0-79953731734
4. Hirayama I., Tamemoto H., Yokota H., Kubo S. K., Wang J., Kuwano H., Nagamachi Y., Takeuchi T., Izumi T., Insulin receptor-related receptor is expressed in pancreatic β -cells and stimulates tyrosine phosphorylation of insulin receptor substrate-1 and- 2. Diabetes 2000 48 6 1237 1244 2-s2.0-0344517365 10.2337/diabetes.48.6.1237 (Pubitemid 29241020)
5. Paris M., Bernard-Kargar C., Vilar J., Kassis N., Ktorza A., Role of glucose in IRS signaling in rat pancreatic islets: specific effects and interplay with insulin. Experimental Diabesity Research 2004 5 4 257 263 2-s2.0-12344259515 10.1080/15438600490905169 (Pubitemid 40123410)
6. Thirone A. C., Huang C., Klip A., Tissue-specific roles of IRS proteins in insulin signaling and glucose transport. Trends in Endocrinology and Metabolism 2006 17 2 72 78 2-s2.0-33646456806 10.1016/j.tem.2006.01.005
7. Saltiel A. R., Kahn C. R., Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001 414 6865 799 806 2-s2.0-0035856949 10.1038/414799a (Pubitemid 34000783)
8. Furtado L. M., Somwar R., Sweeney G., Niu W., Klip A., Activation of the glucose transporter GLUT4 by insulin. Biochemistry and Cell Biology 2002 80 5 569 578 2-s2.0-0036968480 10.1139/o02-156 (Pubitemid 36124818)
9. Chang L., Chiang S. H., Saltiel A. R., Insulin signaling and the regulation of glucose transport. Molecular Medicine 2004 10 7-12 65 71 2-s2.0-29244462334 10.2119/2005-00029.Saltiel (Pubitemid 41825486)
10. Thong F. S. L., Dugani C. B., Klip A., Turning signals on and off: GLUT4 traffic in the insulin-signaling highway. Physiology 2005 4 271 284 2-s2.0-24044468429 (Pubitemid 41215201)
11. Sharma M. D., Garber A. J., Farmer J. A., Role of insulin signaling in maintaining energy homeostasis. Endocrine Practice 2008 14 3 373 380 2-s2.0-48949090967
12. Baumann C. A., Ribon V., Kanzaki M., Thurmond D. C., Mora S., Shigematsu S., Bickel P. E., Pessin J. E., Saltiel A. R., CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 2000 407 6801 202 207 2-s2.0-0034648794 10.1038/35025089
13. Liu J., Kimura A., Baumann C. A., Saltiel A. R., APS facilitates c-Cbl tyrosine phosphorylation and GLUT4 translocation in response to insulin in 3T3-L1 adipocytes. Molecular and Cellular Biology 2002 22 11 3599 3609 2-s2.0-0036098461 10.1128/MCB.22.11.3599-3609.2002 (Pubitemid 34525204)
14. Hu J., Liu J., Ghirlando R., Saltiel A. R., Hubbard S. R., Structural basis for recruitment of the adaptor protein APS to the activated insulin receptor. Molecular Cell 2003 12 6 1379 1389 2-s2.0-0346156078 10.1016/S1097-2765(03)00487-8 (Pubitemid 38037008)
15. Mitra P., Zheng X., Czech M. P., RNAi-based analysis of CAP, Cbl, and CrkII function in the regulation of GLUT4 by insulin. The Journal of Biological Chemistry 2004 279 36 37431 37435 2-s2.0-4444228993 10.1074/jbc.C400180200 (Pubitemid 39195452)
16. Liu J., DeYoung S. M., Zhang M., Dold L. H., Saltiel A. R., The stomatin/prohibitin/flotillin/HflK/C domain of flotillin-1 contains distinct sequences that direct plasma membrane localization and protein interactions in 3T3-L1 adipocytes. The Journal of Biological Chemistry 2005 280 16 16125 16134 2-s2.0-18144396107 10.1074/jbc.M500940200 (Pubitemid 40616737)
17. Egan S. E., Giddings B. W., Brooks M. W., Buday L., Sizeland A. M., Weinberg R. A., Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 1993 362 6424 45 51 2-s2.0-0027910431 (Pubitemid 23144959)
18. Chardin P., Camonis J. H., Gale N. W., Van Aelst L., Schlessinger J., Wigler M. H., Bar-Sagi D., Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science 1993 260 5112 1338 1343 2-s2.0-0027304731 (Pubitemid 23231980)
19. Skolnik E. Y., Batzer A., Li N., Lee C. H., Lowenstein E., Mohammadi M., Margolis B., Schlessinger J., The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 1993 260 5116 1953 1955 2-s2.0-0027182367 (Pubitemid 23258278)
20. Baron V., Van Obberghen E., Mechanism of insulin action. Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales 1995 189 1 25 41 2-s2.0-0029187387
21. Combettes-Souverain M., Issad T., Molecular basis of insulin action. Diabetes and Metabolism 1998 24 6 477 489 2-s2.0-0032430963 (Pubitemid 29048416)
22. Yano Y., Sumida Y., Benzing C. F., Robinson F. W., Kono T., Primary sites of actions of staurosporine and H-7 in the cascade of insulin action to glucose transport in rat adipocytes. Biochimica et Biophysica Acta 1993 1176 3 327 332 2-s2.0-0027462178 10.1016/0167-4889(93)90062-T (Pubitemid 23113776)
23. Sweeney G., Somwar R., Ramlal T., Volchuk A., Ueyama A., Klip A., An inhibitor of p38 mitogen-activated protein kinase prevents insulin- stimulated glucose transport but not glucose transporter translocation in 3T3-L1 adipocytes and L6 myotubes. The Journal of Biological Chemistry 1999 274 15 10071 10078 2-s2.0-0033537853 10.1074/jbc.274.15.10071 (Pubitemid 29180874)
24. Somwar R., Kim D. Y., Sweeney G., Huang C., Niu W., Lador C., Ramlal T., Klip A., GLUT4 translocation precedes the stimulation of glucose uptake by insulin in muscle cells: potential activation of GLUT4 via p38 mitogen-activated protein kinase. Biochemical Journal 2001 359 3 639 649 2-s2.0-0035504158 10.1042/0264-6021:3590639 (Pubitemid 33063389)
25. Nystrom F. H., Quon M., Insulin signalling: metabolic pathways and mechanisms for specificity. Cellular Signalling 1999 11 8 563 574 2-s2.0-0032987220 10.1016/S0898-6568(99)00025-X (Pubitemid 29255888)
26. Liu G., Rondinone C. M., JNK: bridging the insulin signaling and inflammatory pathway. Current Opinion in Investigational Drugs 2005 6 10 979 987 2-s2.0-27544487938 (Pubitemid 41535781)
27. Prudente S., Morini E., Trischitta V., Insulin signaling regulating genes: effect on T2DM and cardiovascular risk. Nature Reviews Endocrinology 2009 5 12 682 693 2-s2.0-70749139756 10.1038/nrendo.2009.215
28. Rains J. L., Jain S. K., Oxidative stress, insulin signaling, and diabetes. Free Radical Biology and Medicine 2011 50 5 567 575 2-s2.0-79551470306 10.1016/j.freeradbiomed.2010.12.006
29. Abdul-Ghani M. A., Defronzo R. A., Pathogenesis of insulin resistance in skeletal muscle. Journal of Biomedicine and Biotechnology 2010 2010 19 476279 2-s2.0-78751644241 10.1155/2010/476279
30. Kontrogianni-Konstantopoulos A., Benian G., Granzier H., Advances in muscle physiology and pathophysiology. Journal of Biomedicine and Biotechnology 2010 2010 1 2-s2.0-77956751011 10.1155/2010/780417 780417
31. Di Carlo M., Picone P., Carrotta R., Giacomazza D., San Biagio P. L., Insulin promotes survival of amyloid-beta oligomers neuroblastoma damaged cells via caspase 9 inhibition and Hsp70 upregulation. Journal of Biomedicine and Biotechnology 2010 2010 8 2-s2.0-77953486096 10.1155/2010/147835 147835
32. Peppa M., Koliaki C., Nikolopoulos P., Raptis S. A., Skeletal muscle insulin resistance in endocrine disease. Journal of Biomedicine and Biotechnology 2010 2010 13 2-s2.0-77951686863 10.1155/2010/527850 527850
33. Kontrogianni-Konstantopoulos A., Benian G., Granzier H., Advances in muscle physiology and pathophysiology 2011. Journal of Biomedicine and Biotechnology 2012 2012 1 930836 2-s2.0-77956751011 10.1155/2012/930836
34. Hirabara S. M., Silveira L. R., Abdulkader F., Carvalho C. R. O., Procopio J., Curi R., Time-dependent effects of fatty acids on skeletal muscle metabolism. Journal of Cellular Physiology 2007 210 1 7 15 2-s2.0-33845444350 10.1002/jcp.20811 (Pubitemid 44904696)
35. Silveira L. R., Fiamoncini J., Hirabara S. M., Procópio J., Cambiaghi T. D., Pinheiro C. H. J., Lopes L. R., Curi R., Updating the effects of fatty acids on skeletal muscle. Journal of Cellular Physiology 2008 217 1 1 12 2-s2.0-49649090886 10.1002/jcp.21514
36. Hirabara S. M., Curi R., Maechler P., Saturated fatty acid-induced insulin resistance is associated with mitochondrial dysfunction in skeletal muscle cells. Journal of Cellular Physiology 2010 222 1 187 194 2-s2.0-73949160860 10.1002/jcp.21936
37. Martins A. R., Nachbar R. T., Gorjao R., Vinolo M. A., Festuccia W. T., Lambertucci R. H., Cury-Boaventura M. F., Silveira L. R., Curi R., Hirabara S. M., Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids in Health and Disease 2012 11, article 30 2-s2.0-84857352823 10.1186/1476-511X-11-30
38. Shulman G. I., Cellular mechanisms of insulin resistance. The Journal of Clinical Investigation 2000 106 2 171 176 2-s2.0-0033927667 (Pubitemid 30483118)
39. Roden M., How free fatty acids inhibit glucose utilization in human skeletal muscle. News in Physiological Sciences 2004 19 3 92 96 2-s2.0-3042841952 10.1152/nips.01459.2003
40. Yu C., Chen Y., Cline G. W., Zhang D., Zong H., Wang Y., Bergeron R., Kim J. K., Cushman S. W., Cooney G. J., Atcheson B., White M. F., Kraegen E. W., Shulman G. I., Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. The Journal of Biological Chemistry 2002 277 52 50230 50236 2-s2.0-0037184925 10.1074/jbc.M200958200 (Pubitemid 36042170)
41. Newsholme P., Haber E. P., Hirabara S. M., Rebelato E. L. O., Procopio J., Morgan D., Oliveira-Emilio H. C., Carpinelli A. R., Curi R., Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. Journal of Physiology 2007 583 1 9 24 2-s2.0-34547830983 10.1113/jphysiol.2007.135871 (Pubitemid 47244241)
42. Randle P. J., Garland P. B., Hales C. N., Newsholme E. A., The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. The Lancet 1963 281 7285 785 789 2-s2.0-50549202600
43. Roden M., Price T. B., Perseghin G., Petersen K. F., Rothman D. L., Cline G. W., Shulman G. I., Mechanism of free fatty acid-induced insulin resistance in humans. The Journal of Clinical Investigation 1996 97 12 2859 2865 2-s2.0-0029948212 (Pubitemid 26197099)
44. Griffin M. E., Marcucci M. J., Cline G. W., Bell K., Barucci N., Lee D., Goodyear L. J., Kraegen E. W., White M. F., Shulman G. I., Free fatty acid-induced insulin resistance is associated with activation of protein kinase C θ and alterations in the insulin signaling cascade. Diabetes 2000 48 6 1270 1274 2-s2.0-0345086474 10.2337/diabetes.48.6.1270 (Pubitemid 29241025)
45. Massao Hirabara S., De Oliveira Carvalho C. R., Mendonça J. R., Piltcher Haber E., Fernandes L. C., Curi R., Palmitate acutely raises glycogen synthesis in rat soleus muscle by a mechanism that requires its metabolization (Randle cycle). FEBS Letters 2003 541 1-3 109 114 2-s2.0-0037464454 10.1016/S0014-5793(03)00316-8 (Pubitemid 36428927)
46. Carvalho-Filho M. A., Ueno M., Hirabara S. M., Seabra A. B., Carvalheira J. B. C., De Oliveira M. G., Velloso L. A., Curi R., Saad M. J. A., S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: a novel mechanism of insulin resistance. Diabetes 2005 54 4 959 967 2-s2.0-15944378147 10.2337/diabetes.54.4.959 (Pubitemid 40446309)
47. Brehm A., Krssak M., Schmid A. I., Nowotny P., Waldhäusl W., Roden M., Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. Diabetes 2006 55 1 136 140 2-s2.0-33644746318 10.2337/diabetes.55.1.136 (Pubitemid 43343308)
48. Lenoir O., Flosseau K., Ma F. X., Blondeau B., Mai A., Bassel-Duby R., Ravassard P., Olson E. N., Haumaitre C., Scharfmann R., Specific control of pancreatic endocrine β-and δ -cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9. Diabetes 2011 60 11 2861 2871 2-s2.0-80755168896 10.2337/db11-0440
49. Rajendran R., Garva R., Krstic-Demonacos M., Demonacos C., Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription. Journal of Biomedicine and Biotechnology 2011 2011 17 368276 2-s2.0-81555226055 10.1155/2011/368276
50. Murata M., Thanan R., Ma N., Kawanishi S., Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis. Journal of Biomedicine and Biotechnology 2012 2012 11 623019 2-s2.0-84858116393 10.1155/2012/623019
51. Bashan N., Kovsan J., Kachko I., Ovadia H., Rudich A., Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiological Reviews 2009 89 1 27 71 2-s2.0-58249110569 10.1152/physrev.00014.2008
52. Zhang L., Haraguchi S., Koda T., Hashimoto K., Nakagawara A., Muscle atrophy and motor neuron degeneration in human NEDL1 transgenic mice. Journal of Biomedicine and Biotechnology 2011 2011 7 2-s2.0-78349267592 10.1155/2011/831092 831092
53. Evans J. L., Lin J. J., Goldfine I. D., Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta. Current Diabetes Reviews 2005 1 3 299 307 2-s2.0-33749993658
54. Henriksen E. J., Diamond-Stanic M. K., Marchionne E. M., Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radical Biology and Medicine 2011 51 5 993 999 2-s2.0-78650929819 10.1016/j. freeradbiomed.2010.12.005
55. Lim J. H., Lee J. I., Suh Y. H., Kim W., Song J. H., Jung M. H., Mitochondrial dysfunction induces aberrant insulin signalling and glucose utilisation in murine C2C12 myotube cells. Diabetologia 2006 49 8 1924 1936 2-s2.0-33745769040 10.1007/s00125-006-0278-4 (Pubitemid 44025048)
56. Guo W. X., Pye Q. N., Williamson K. S., Stewart C. A., Hensley K. L., Kotake Y., Floyd R. A., Broyles R. H., Mitochondrial dysfunction in choline deficiency-induced apoptosis in cultured rat hepatocytes. Free Radical Biology and Medicine 2005 39 5 641 650 2-s2.0-23444454346 10.1016/j.freeradbiomed.2005. 04.013 (Pubitemid 41112105)
57. Wallace J. P., Johnson B., Padilla J., Mather K., Postprandial lipaemia, oxidative stress and endothelial function: a review. International Journal of Clinical Practice 2010 64 3 389 403 2-s2.0-74349107208 10.1111/j.1742-1241.2009. 02146.x
58. Medzhitov R., Origin and physiological roles of inflammation. Nature 2008 454 7203 428 435 2-s2.0-47949099098 10.1038/nature07201
59. Lumeng C. N., Saltiel A. R., Inflammatory links between obesity and metabolic disease. The Journal of Clinical Investigation 2011 121 6 2111 2117 2-s2.0-79957920754 10.1172/JCI57132
60. Hotamisligil G. S., Inflammation and metabolic disorders. Nature 2006 444 7121 860 867 2-s2.0-33845866857 10.1038/nature05485 (Pubitemid 46024993)
61. Sun K., Kusminski C. M., Scherer P. E., Adipose tissue remodeling and obesity. The Journal of Clinical Investigation 2011 121 6 2094 2101 2-s2.0-79957916782 10.1172/JCI45887
62. Mothe-Satney I., Filloux C., Amghar H., Pons C., Bourlier V., Galitzky J., Grimaldi P. A., Féral C. C., Bouloumié A., Van Obberghen E., Neels J. G., Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice. Diabetes 2012 61 9 2311 2319 2-s2.0-84865497318 10.2337/db11-1455
63. Kurokaw J., Nagano H., Ohara O., Kubota N., Kadowaki T., Arai S., Miyazaki T., Apoptosis inhibitor of macrophage (AIM) is required for obesity-associated recruitment of inflammatory macrophages into adipose tissue. Proceedings of the National Academy of Sciences of the United States of America 2011 108 29 12072 12077 2-s2.0-79961038025 10.1073/pnas.1101841108
64. Lanthier N., Molendi-Coste O., Horsmans Y., Van Rooijen N., Cani P. D., Leclercq I. A., Kupffer cell activation is a causal factor for hepatic insulin resistance. American Journal of Physiology 2010 298 1 G107 G116 2-s2.0-73549090090 10.1152/ajpgi.00391.2009
65. + effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nature Medicine 2009 15 8 914 920 2-s2.0-68349150756 10.1038/nm.1964
66. Feuerer M., Herrero L., Cipolletta D., Naaz A., Wong J., Nayer A., Lee J., Goldfine A. B., Benoist C., Shoelson S., Mathis D., Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nature Medicine 2009 15 8 930 939 2-s2.0-68349148211 10.1038/nm.2002
67. Rocha V. Z., Folco E. J., Sukhova G., Shimizu K., Gotsman I., Vernon A. H., Libby P., Interferon- γ a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circulation Research 2008 103 5 467 476 2-s2.0-54049086276 10.1161/CIRCRESAHA.108.177105
68. Bertola A., Ciucci T., Rousseau D., Bourlier V., Duffaut C., Bonnafous S., Blin-Wakkach C., Anty R., Iannelli A., Gugenheim J., Tran A., Bouloumié A., Gual P., Wakkach A., Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes 2012 61 9 2238 2247 2-s2.0-84865461206 10.2337/db11-1274
69. Davis H. M., Carpenter D. C., Stahl J. M., Zhang W., Hynicka W. P., Griswold D. E., Human granulocyte CD11b expression as a pharmacodynamic biomarker of inflammation. Journal of Immunological Methods 2000 240 1-2 125 132 2-s2.0-0034705657 10.1016/S0022-1759(00)00183-6 (Pubitemid 30347408)
70. Hotamisligil G. S., Shargill N. S., Spiegelman B. M., Adipose expression of tumor necrosis factor- α: direct role in obesity-linked insulin resistance. Science 1993 259 5091 87 91 2-s2.0-0027459878 (Pubitemid 23036092)
71. Haruta T., Uno T., Kawahara J., Takano A., Egawa K., Sharma P. M., Olefsky J. M., Kobayashi M., A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Molecular Endocrinology 2000 14 6 783 794 2-s2.0-0034463918 10.1210/me.14.6.783 (Pubitemid 32260492)
72. Gual P., Le Marchand-Brustel Y., Tanti J. F., Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 2005 87 1 99 109 2-s2.0-14544271905 10.1016/j.biochi.2004.10.019 (Pubitemid 40298772)
73. Hiratani K., Haruta T., Tani A., Kawahara J., Usui I., Kobayashi M., Roles of mTOR and JNK in serine phosphorylation, translocation, and degradation of IRS-1. Biochemical and Biophysical Research Communications 2005 335 3 836 842 2-s2.0-23944475571 10.1016/j.bbrc.2005.07.152 (Pubitemid 41188274)
74. Tsukumo D. M. L., Carvalho-Filho M. A., Carvalheira J. B. C., Prada P. O., Hirabara S. M., Schenka A. A., Araújo E. P., Vassallo J., Curi R., Velloso L. A., Saad M. J. A., Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007 56 8 1986 1998 2-s2.0-34547602916 10.2337/db06-1595 (Pubitemid 47195825)
75. Wu F., Liu Y., Lv X., Miao X., Sun Y., Yu W., Small interference RNA targeting TLR4 gene effectively attenuates pulmonary inflammation in a rat model. Journal of Biomedicine and Biotechnology 2012 2012 8 406435 2-s2.0-84863279168 10.1155/2012/406435
76. Hirosumi J., Tuncman G., Chang L., Görgün C. Z., Uysal K. T., Maeda K., Karin M., Hotamisligil G. S., A central, role for JNK in obesity and insulin resistance. Nature 2002 420 6913 333 336 2-s2.0-0037153158 10.1038/nature01137 (Pubitemid 35398190)
77. Kaneto H., Nakatani Y., Kawamori D., Miyatsuka T., Matsuoka T. A., Matsuhisa M., Yamasaki Y., Role of oxidative stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase in pancreatic β -cell dysfunction and insulin resistance. International Journal of Biochemistry and Cell Biology 2006 38 5-6 782 793 2-s2.0-33644845569 10.1016/j.biocel.2006.01.004 (Pubitemid 43363411)
78. Solinas G., Naugler W., Galimi F., Lee M. S., Karin M., Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proceedings of the National Academy of Sciences of the United States of America 2006 103 44 16454 16459 2-s2.0-33750823407 10.1073/pnas.0607626103 (Pubitemid 44715217)
79. Håversen L., Danielsson K. N., Fogelstrand L., Wiklund O., Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages. Atherosclerosis 2009 202 2 382 393 2-s2.0-58549105701 10.1016/j.atherosclerosis.2008.05.033
80. Wen H., Gris D., Lei Y., Jha S., Zhang L., Huang M. T. H., Brickey W. J., Ting J. P. Y., Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nature Immunology 2011 12 5 408 415 2-s2.0-79955038882 10.1038/ni.2022
81. Coletta D. K., Mandarino L. J., Mitochondrial dysfunction and insulin resistance from the outside in: extracellular matrix, the cytoskeleton, and mitochondria. 2011 301 5 E749 E755 2-s2.0-84865525046 10.1152/ajpendo.00363.2011
82. Bunn R. C., Cockrell G. E., Ou Y., Thrailkill K. M., Lumpkin C. K., Fowlkes J. L., Palmitate and insulin synergistically induce IL-6 expression in human monocytes. Cardiovascular Diabetology 2010 9, article 73 2-s2.0-78049408569 10.1186/1475-2840-9-73
83. Ji C., Chen X., Gao C., Jiao L., Wang J., Xu G., Fu H., Guo X., Zhao Y., IL-6 induces lipolysis and mitochondrial dysfunction, but does not affect insulin-mediated glucose transport in 3T3-L1 adipocytes. Journal of Bioenergetics and Biomembranes 2011 43 4 367 375 2-s2.0-79959803396 10.1007/s10863-011-9361-8
84. Yasuhara R., Miyamoto Y., Akaike T., Akuta T., Nakamura M., Takami M., Morimura N., Yasu K., Kamijo R., Interleukin-1 β induces death in chondrocyte-like ATDC5 cells through mitochondrial dysfunction and energy depletion in a reactive nitrogen and oxygen species-dependent manner. Biochemical Journal 2005 389 2 315 323 2-s2.0-22544432235 10.1042/BJ20041996 (Pubitemid 41021134)
85. Ofei F., Hurel S., Newkirk J., Sopwith M., Taylor R., Effects of an engineered human anti-TNF- α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996 45 3 881 885 2-s2.0-0029906375 (Pubitemid 26225502)
86. Bernstein L. E., Berry J., Kim S., Canavan B., Grinspoon S. K., Effects of etanercept in patients with the metabolic syndrome. Archives of Internal Medicine 2006 166 8 902 908 2-s2.0-33646134126 10.1001/archinte.166.8.902
87. Dominguez H., Storgaard H., Rask-Madsen C., Hermann T. S., Ihlemann N., Nielsen D. B., Spohr C., Kober L., Vaag A., Torp-Pedersen C., Metabolic and vascular effects of tumor necrosis factor- α blockade with etanercept in obese patients with type 2 diabetes. Journal of Vascular Research 2005 42 6 517 525 2-s2.0-27344441019 10.1159/000088261 (Pubitemid 41527607)
88. Paquot N., Castillo M. J., Lefèbvre P. J., Scheen A. J., No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. Journal of Clinical Endocrinology and Metabolism 2000 85 3 1316 1319 2-s2.0-0034454915 10.1210/jc.85.3.1316 (Pubitemid 32269392)
89. Wascher T. C., Lindeman J. H. N., Sourij H., Kooistra T., Pacini G., Roden M., Chronic TNF- α neutralization does not improve insulin resistance or endothelial function in "healthy" men with metabolic syndrome. Molecular Medicine 2011 17 3-4 189 193 2-s2.0-79952856377 10.2119/molmed.2010.00221
90. Gonzalez-Gay M. A., De Matias J. M., Gonzalez-Juanatey C., Garcia-Porrua C., Sanchez-Andrade A., Martin J., Llorca J., Anti-tumor necrosis factor- α blockade improves insulin resistance in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2006 24 1 83 86 2-s2.0-33645082929
91. Gonzalez-Gay M. A., Gonzalez-Juanatey C., Vazquez-Rodriguez T. R., Miranda-Filloy J. A., Llorca J., Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF- α therapy: annals of the New York Academy of Sciences. Annals of the New York Academy of Sciences 2010 1193 153 159 2-s2.0-77951227180 10.1111/j.1749-6632.2009.05287.x
92. Seriolo B., Paolino S., Ferrone C., Cutolo M., Impact of long-term anti-TNF- α treatment on insulin resistance in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2008 26 1, article 159 2-s2.0-40749101528
93. Tam L. S., Tomlinson B., Chu T. T., Li T. K., Li E. K., Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clinical Rheumatology 2007 26 9 1495 1498 2-s2.0-34547631047 10.1007/s10067-007-0539-8 (Pubitemid 47201685)
94. Miranda-Filloy J. A., Llorca J., Carnero-Lopez B., Gonzalez-Juanatey C., Blanco R., Gonzalez-Gay M. A., TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clinical and Experimental Rheumatology. In press
95. Stagakis I., Bertsias G., Karvounaris S., Kavousanaki M., Virla D., Raptopoulou A., Kardassis D., Boumpas D. T., Sidiropoulos P. I., Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Research and Therapy 2012 14 3, article 141 2-s2.0-84861991838 10.1186/ar3874
96. Ridker P. M., Thuren T., Zalewski A., Libby P., Interleukin-1 β inhibition and the prevention of recurrent cardiovascular events: rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). American Heart Journal 2011 162 4 597 605 2-s2.0-84862995012 10.1016/j.ahj.2011.06.012
97. Cho H., Black S. C., Looper D., Shi M., Kelly-Sullivan D., Timofeevski S., Siegel K., Yu X. H., McDonnell S. R., Chen P., Yie J., Ogilvie K. M., Fraser J., Briscoe C. P., Pharmacological characterization of a small molecule inhibitor of c-Jun kinase. American Journal of Physiology 2008 295 5 E1142 E1151 2-s2.0-57049105164 10.1152/ajpendo.90298.2008
98. Stebbins J. L., De S. K., Machleidt T., Becattini B., Vazquez J., Kuntzen C., Chen L. H., Cellitti J. F., Riel-Mehan M., Emdadi A., Solinas G., Karin M., Pellecchia M., Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proceedings of the National Academy of Sciences of the United States of America 2008 105 43 16809 16813 2-s2.0-55949100580 10.1073/pnas.0805677105
99. Stebbins J. L., De S. K., Pavlickova P., Chen V., MacHleidt T., Chen L.-H., Kuntzen C., Kitada S., Karin M., Pellecchia M., Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor. Journal of Medicinal Chemistry 2011 54 18 6206 6214 2-s2.0-80052815074 10.1021/jm200479c
100. Feng X., Wang W., Liu J., Liu Y., β -Arrestins: multifunctional signaling adaptors in type 2 diabetes. Molecular Biology Reports 2011 38 4 2517 2528 2-s2.0-79960940602 10.1007/s11033-010-0389-3
101. Mayor F., Lucas E., Jurado-Pueyo M., Garcia-Guerra L., Nieto-Vazquez I., Vila-Bedmar R., Fernández-Veledo S., Murga C., G Protein-coupled receptor kinase 2 (GRK2): a novel modulator of insulin resistance. Archives of Physiology and Biochemistry 2011 117 3 125 130 2-s2.0-79959199413 10.3109/13813455.2011.584693
102. Vinolo M. A. R., Hirabara S. M., Curi R., G-protein-coupled receptors as fat sensors. Current Opinion in Clinical Nutrition and Metabolic Care 2012 15 2 112 116 2-s2.0-84857041125 10.1097/MCO.0b013e32834f4598
103. Tuo Y., Feng D. D., Wang D.-F., Sun J., Li S.-B., Chen C., Long-term in vitro treatment of INS-1 rat pancreatic β -cells by unsaturated free fatty acids protects cells against gluco- and lipotoxicities via activation of GPR40 receptors. Clinical and Experimental Pharmacology and Physiology 2012 39 5 423 428 2-s2.0-84860250275 10.1111/j.1440-1681.2012.05691.x
104. Chu Z. L., Jones R. M., He H., Carroll C., Gutierrez V., Lucman A., Moloney M., Gao H., Mondala H., Bagnol D., Unett D., Liang Y., Demarest K., Semple G., Behan D. P., Leonard J., A role for β -cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007 148 6 2601 2609 2-s2.0-34248527678 10.1210/en.2006-1608 (Pubitemid 46984798)
105. Edfalk S., Steneberg P., Edlund H., Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008 57 9 2280 2287 2-s2.0-52749098923 10.2337/db08-0307
106. Hirasawa A., Tsumaya K., Awaji T., Katsuma S., Adachi T., Yamada M., Sugimoto Y., Miyazaki S., Tsujimoto G., Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nature Medicine 2005 11 1 90 94 2-s2.0-13444263540 10.1038/nm1168 (Pubitemid 40215843)
107. Hansen K. B., Rosenkilde M. M., Knop F. K., Wellner N., Diep T. A., Rehfeld J. F., Andersen U. B., Holst J. J., Hansen H. S., 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. Journal of Clinical Endocrinology and Metabolism 2011 96 9 E1409 E1417 2-s2.0-80052521074 10.1210/jc.2011-0647
108. Lauffer L. M., Iakoubov R., Brubaker P. L., GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 2009 58 5 1058 1066 2-s2.0-65549142522 10.2337/db08-1237
109. Tolhurst G., Heffron H., Lam Y. S., Parker H. E., Habib A. M., Diakogiannaki E., Cameron J., Grosse J., Reimann F., Gribble F. M., Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012 61 2 364 371 2-s2.0-84856509724 10.2337/db11-1019
110. Oh D. Y., Talukdar S., Bae E. J., Imamura T., Morinaga H., Fan W., Li P., Lu W. J., Watkins S. M., Olefsky J. M., GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010 142 5 687 698 2-s2.0-77956165390 10.1016/j.cell.2010.07.041
111. Glozak M. A., Sengupta N., Zhang X., Seto E., Acetylation and deacetylation of non-histone proteins. Gene 2005 363 1-2 15 23 2-s2.0-28044471827 10.1016/j.gene.2005.09.010 (Pubitemid 41691888)
112. Grabiec A. M., Tak P. P., Reedquist K. A., Function of histone deacetylase inhibitors in inflammation. Critical Reviews in Immunology 2011 31 3 233 263 2-s2.0-79959301511
113. Christensen D. P., Dahllöf M., Lundh M., Rasmussen D. N., Nielsen M. D., Billestrup N., Grunnet L. G., Mandrup-Poulsen T., Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Molecular Medicine 2011 17 5-6 378 390 2-s2.0-79957944601 10.2119/molmed.2011.00021
114. Lewis E. C., Blaabjerg L., StØrling J., Ronn S. G., Mascagni P., Dinarello C. A., Mandrup-Poulsen T., The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro. Molecular Medicine 2011 17 5-6 369 377 2-s2.0-79957949655 10.2119/molmed.2010. 00152
115. Gao Z., Yin J., Zhang J., Ward R. E., Martin R. J., Lefevre M., Cefalu W. T., Ye J., Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009 58 7 1509 1517 2-s2.0-67649238355 10.2337/db08-1637
116. Vinolo M. A. R., Rodrigues H. G., Festuccia W. T., Crisma A. R., Alves V. S., Martins A. R., Amaral C. L., Fiamoncini J., Hirabara S. M., Sato F. T., Fock R. A., Malheiros G., dos Santos M. F., Curi R., Tributyrin attenuates obesity-associated inflammation and insulin resistance in high-fat-fed mice. American Journal of Physiology 2012 303 2 E272 E282 2-s2.0-84863952154 10.1152/ajpendo.00053.2012
117. Li H., Gao Z., Zhang J., Ye X., Xu A., Ye J., Jia W., Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes 2012 61 4 797 806 2-s2.0-84859529243 10.2337/db11-0846
118. Winkler R., Benz V., Clemenz M., Bloch M., Foryst-Ludwig A., Wardat S., Witte N., Trappiel M., Namsolleck P., Mai K., Spranger J., Matthias G., Roloff T., Truee O., Kappert K., Schupp M., Matthias P., Kintscher U., Histone deacetylase 6 (HDAC6) is an essential modifier of glucocorticoid-induced hepatic gluconeogenesis. Diabetes 2012 61 2 513 523 2-s2.0-84863228630 10.2337/db11-0313
119. Saouaf S. J., Li B., Zhang G., Shen Y., Furuuchi N., Hancock W. W., Greene M. I., Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Experimental and Molecular Pathology 2009 87 2 99 104 2-s2.0-70349385423 10.1016/j.yexmp.2009. 06.003
120. Tao R., De Zoeten E. F., Özkaynak E., Chen C., Wang L., Porrett P. M., Li B., Turka L. A., Olson E. N., Greene M. I., Wells A. D., Hancock W. W., Deacetylase inhibition promotes the generation and function of regulatory T cells. Nature Medicine 2007 13 11 1299 1307 2-s2.0-35948980739 10.1038/nm1652
121. Chiarelli F., Di Marzio D., Peroxisome proliferator-activated receptor- γ agonists and diabetes: current evidence and future perspectives. Vascular Health and Risk Management 2008 4 2 297 304 2-s2.0-44049108337 (Pubitemid 351711958)
122. Guo N., Woeller C. F., Feldon S. E., Phipps R. P., Peroxisome proliferator-activated receptor γ ligands inhibit transforming growth factor- β -induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts. The Journal of Biological Chemistry 2011 286 21 18856 18867 2-s2.0-79956334409 10.1074/jbc.M110.179317
123. Hamblin M., Chang L., Zhang H., Yang K., Zhang J., Chen Y. E., Vascular smooth muscle cell peroxisome proliferator-activated receptor- γ mediates pioglitazone-reduced vascular lesion formation. Arteriosclerosis, Thrombosis, and Vascular Biology 2011 31 2 352 359 2-s2.0-79551471791 10.1161/ATVBAHA.110. 219006
124. Foryst-Ludwig A., Hartge M., Clemenz M., Sprang C., Heß K., Marx N., Unger T., Kintscher U., PPARgamma activation attenuates T-lymphocyte- dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovascular Diabetology 2010 9, article 64 2-s2.0-77957919796 10.1186/1475-2840-9-64
125. Ye Y. L., Zhou Z., Zou H. J., Shen Y., Xu T. F., Tang J., Yin H. Z., Chen M. L., Leng Y., Shen J. H., Discovery of novel dual functional agent as PPAR γ agonist and 11 β -HSD1 inhibitor for the treatment of diabetes. Bioorganic and Medicinal Chemistry 2009 17 15 5722 5732 2-s2.0-67651094103 10.1016/j.bmc.2009.05.082
126. Zhang Y. F., Yang X., Zhang Y. J., Sun Y. L., Zou X. L., Kong Q. Y., Dong X. Q., Ye X. Q., Yu X. Q., Peroxisome proliferator-activated receptor-gamma is expressed by rat peritoneal mesothelial cells: its potential role in peritoneal cavity local defense. American Journal of Nephrology 2007 26 6 602 611 2-s2.0-33846441237 10.1159/000098149 (Pubitemid 46143882)
127. Suzawa M., Takada I., Yanagisawa J., Ohtake F., Ogawa S., Yamauchi T., Kadowaki T., Takeuchi Y., Shibuya H., Gotoh Y., Matsumoto K., Kato S., Cytokines suppress adipogenesis and PPAR- γ function through the TAK1/TAB1/NIK cascade. Nature Cell Biology 2003 5 3 224 230 2-s2.0-0037342133 10.1038/ncb942 (Pubitemid 36322249)
128. Lumeng C. N., DeYoung S. M., Bodzin J. L., Saltiel A. R., Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007 56 1 16 23 2-s2.0-33847073149 10.2337/db06-1076
129. Tilg H., Moschen A. R., Inflammatory mechanisms in the regulation of insulin resistance. Molecular Medicine 2008 14 3-4 222 231 2-s2.0-41649093318 10.2119/2007-00119.Tilg (Pubitemid 351481853)
130. Odegaard J. I., Ricardo-Gonzalez R. R., Goforth M. H., Morel C. R., Subramanian V., Mukundan L., Eagle A. R., Vats D., Brombacher F., Ferrante A. W., Chawla A., Macrophage-specific PPAR γ controls alternative activation and improves insulin resistance. Nature 2007 447 7148 1116 1120 2-s2.0-34347354309 10.1038/nature05894 (Pubitemid 47014427)
131. Cipolletta D., Feuerer M., Li A., Kamei N., Lee J., Shoelson S. E., Benoist C., Mathis D., PPAR- γ is a major driver of the accumulation and phenotype of adipose tissue T reg cells. Nature 2012 486 7404 549 553 2-s2.0-84862986986 10.1038/nature11132
132. Zheng F., Guan Y., Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy? Kidney International 2007 72 11 1301 1303 2-s2.0-36248983781 10.1038/sj.ki.5002557 (Pubitemid 350126785)
133. Sakaguchi S., Yamaguchi T., Nomura T., Ono M., Regulatory T cells and immune tolerance. Cell 2008 133 5 775 787 2-s2.0-43949105866 10.1016/j.cell.2008.05.009 (Pubitemid 351707693)
134. Feuerer M., Shen Y., Littman D. R., Benoist C., Mathis D., How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 2009 31 4 654 664 2-s2.0-70349755645 10.1016/j.immuni.2009.08.023
135. Wu K., Bi Y., Sun K., Wang C., IL-10-producing type 1 regulatory T cells and allergy. Cellular & Molecular Immunology 2007 4 4 269 275 2-s2.0-35748951015
136. De Rosa V., Procaccini C., Calì G., Pirozzi G., Fontana S., Zappacosta S., La Cava A., Matarese G., A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007 26 2 241 255 2-s2.0-33847312289 10.1016/j.immuni.2007.01.011 (Pubitemid 46329441)
137. Aderem A., Ulevitch R. J., Toll-like receptors in the induction of the innate immune response. Nature 2000 406 6797 782 787 2-s2.0-0034680145 10.1038/35021228
138. Shi D., Das J., Das G., Inflammatory bowel disease requires the interplay between innate and adaptive immune signals. Cell Research 2006 16 1 70 74 2-s2.0-31144445210 10.1038/sj.cr.7310009 (Pubitemid 43129310)
139. Dasu M. R., Devaraj S., Park S., Jialal I., Increased Toll-Like Receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010 33 4 861 868 2-s2.0-77953060025 10.2337/dc09-1799
140. Mohammad M. K., Morran M., Slotterbeck B., Leaman D. W., Sun Y., von Grafenstein H., Hong S. C., McInerney M. F., Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. International Immunology 2006 18 7 1101 1113 2-s2.0-33745251699 10.1093/intimm/dxl045 (Pubitemid 43923428)
141. Kim H. S., Han M. S., Chung K. W., Kim S., Kim E., Kim M. J., Jang E., Lee H. A., Youn J., Akira S., Lee M. S., Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 2007 27 2 321 333 2-s2.0-34548036686 10.1016/j.immuni.2007.06.010 (Pubitemid 47284922)
142. Kopp A., Buechler C., Bala M., Neumeier M., Schölmerich J., Schäffler A., Toll-like receptor ligands cause proinflammatory and prodiabetic activation of adipocytes via phosphorylation of extracellular signal-regulated kinase and c-Jun N-terminal kinase but not interferon regulatory factor-3. Endocrinology 2010 151 3 1097 1108 2-s2.0-77149175962 10.1210/en.2009-1140
143. Davis J. E., Gabler N. K., Walker-Daniels J., Spurlock M. E., Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity 2008 16 6 1248 1255 2-s2.0-44449110675 10.1038/oby.2008.210 (Pubitemid 351770507)
144. Glass C. K., Olefsky J. M., Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metabolism 2012 15 5 635 645 2-s2.0-84860441011 10.1016/j.cmet.2012.04.001
145. Serhan C. N., Hong S., Gronert K., Colgan S. P., Devchand P. R., Mirick G., Moussignac R. L., Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. Journal of Experimental Medicine 2002 196 8 1025 1037 2-s2.0-0037152160 10.1084/jem.20020760 (Pubitemid 35231761)
146. Clish C. B., O'Brien J. A., Gronert K., Stahl G. L., Petasis N. A., Serhan C. N., Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proceedings of the National Academy of Sciences of the United States of America 1999 96 14 8247 8252 2-s2.0-0033529195 10.1073/pnas.96.14.8247 (Pubitemid 29328440)
147. Mukherjee P. K., Marcheselli V. L., Barreiro S., Hu J., Bok D., Bazan N. G., Neurotrophins enhance retinal pigment epithelial cell survival through neuroprotectin D1 signaling. Proceedings of the National Academy of Sciences of the United States of America 2007 104 32 13152 13157 2-s2.0-34548711717 10.1073/pnas.0705949104 (Pubitemid 351737608)
148. Serhan C. N., Gotlinger K., Hong S., Lu Y., Siegelman J., Baer T., Yang R., Colgan S. P., Petasis N. A., Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. Journal of Immunology 2006 176 3 1848 1859 2-s2.0-33644837614 (Pubitemid 43134330)
149. Godson C., Brady H. R., Lipoxins: novel anti-inflammatory therapeutics? Current Opinion in Investigational Drugs 2000 1 3 380 385 2-s2.0-0033693332
150. González-Périz A., Horrillo R., Ferré N., Gronert K., Dong B., Morán-Salvador E., Titos E., Martínez-Clemente M., López-Parra M., Arroyo V., Clària J., Obesity-induced insulin resistance and hepatic steatosis are alleviated by ω -3 fatty acids: a role for resolvins and protectins. The FASEB Journal 2009 23 6 1946 1957 2-s2.0-67649363782 10.1096/fj.08-125674
151. White P. J., Arita M., Taguchi R., Kang J. X., Marette A., Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes 2010 59 12 3066 3073 2-s2.0-78650060401 10.2337/db10-0054
152. Horrillo R., González-Périz A., Martínez-Clemente M., López-Parra M., Ferré N., Titos E., Morán-Salvador E., Deulofeu R., Arroyo V., Clària J., 5-Lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. Journal of Immunology 2010 184 7 3978 3987 2-s2.0-77951630780 10.4049/jimmunol.0901355
153. Titos E., Rius B., González-Périz A., López-Vicario C., Morán-Salvador E., Martínez-Clemente M., Arroyo V., Clària J., Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. Journal of Immunology 2011 187 10 5408 5418 2-s2.0-81455131791 10.4049/jimmunol.1100225
154. Hellmann J., Tang Y., Kosuri M., Bhatnagar A., Spite M., Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. The FASEB Journal 2011 25 7 2399 2407 2-s2.0-79960187627 10.1096/fj.10-178657
155. Ambros V., The functions of animal microRNAs. Nature 2004 431 7006 350 355 2-s2.0-4644309196 10.1038/nature02871 (Pubitemid 39265675)
156. Bartel D. P., MicroRNAs: target recognition and regulatory functions. Cell 2009 136 2 215 233 2-s2.0-58249088751 10.1016/j.cell.2009.01.002
157. Yu A. M., Role of microRNAs in the regulation of drug metabolism and disposition. Expert Opinion on Drug Metabolism and Toxicology 2009 5 12 1513 1528 2-s2.0-71049182620 10.1517/17425250903307448
158. Bentwich I., Avniel A., Karov Y., Aharonov R., Gilad S., Barad O., Barzilai A., Einat P., Einav U., Meiri E., Sharon E., Spector Y., Bentwich Z., Identification of hundreds of conserved and nonconserved human microRNAs. Nature Genetics 2005 37 7 766 770 2-s2.0-22844440427 10.1038/ng1590 (Pubitemid 41754896)
159. Friedman R. C., Farh K. K. H., Burge C. B., Bartel D. P., Most mammalian mRNAs are conserved targets of microRNAs. Genome Research 2009 19 1 92 105 2-s2.0-60149095444 10.1101/gr.082701.108
160. Small E. M., Olson E. N., Pervasive roles of microRNAs in cardiovascular biology. Nature 2011 469 7330 336 342 2-s2.0-78751660177 10.1038/nature09783
161. Moore K. J., Rayner K. J., Suárez Y., Fernández-Hernando C., The role of MicroRNAs in cholesterol efflux and hepatic lipid metabolism. Annual Review of Nutrition 2011 31 49 63 2-s2.0-79960523356 10.1146/annurev- nutr-081810-160756
162. Lu J., Getz G., Miska E. A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B. L., Mak R. H., Ferrando A. A., Downing J. R., Jacks T., Horvitz H. R., Golub T. R., MicroRNA expression profiles classify human cancers. Nature 2005 435 7043 834 838 2-s2.0-20444460289 10.1038/nature03702 (Pubitemid 40839735)
163. Underbayev C., Kasar S., Yuan Y., Raveche E., MicroRNAs and induced pluripotent stem cells for human disease mouse modeling. Journal of Biomedicine and Biotechnology 2012 2012 7 758169 2-s2.0-84861083702 10.1155/2012/758169
164. Ju J., MiRNAs as biomarkers in colorectal cancer diagnosis and prognosis. Bioanalysis 2010 2 5 901 906 2-s2.0-79952520038 10.4155/bio.10.45
165. Schwarzenbach H., Hoon D. S. B., Pantel K., Cell-free nucleic acids as biomarkers in cancer patients. Nature Reviews Cancer 2011 11 6 426 437 2-s2.0-79957458567 10.1038/nrc3066
166. Xie H., Lim B., Lodish H. F., MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 2009 58 5 1050 1057 2-s2.0-65549144017 10.2337/db08-1299
167. Hulsmans M., De Keyzer D., Holvoet P., MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis. The FASEB Journal 2011 25 8 2515 2527 2-s2.0-79960175448 10.1096/fj.11-181149
168. Frost R. J. A., Olson E. N., Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proceedings of the National Academy of Sciences of the United States of America 2011 108 52 21075 21080 2-s2.0-84855518254 10.1073/pnas.1118922109
169. Harmancey R., Wilson C. R., Taegtmeyer H., Adaptation and maladaptation of the heart in obesity. Hypertension 2008 52 2 181 187 2-s2.0-49849098602 10.1161/HYPERTENSIONAHA.108.110031
170. Grueter C. E., Van Rooij E., Johnson B. A., Deleon S. M., Sutherland L. B., Qi X., Gautron L., Elmquist J. K., Bassel-Duby R., Olson E. N., A cardiac MicroRNA governs systemic energy homeostasis by regulation of MED13. Cell 2012 149 3 671 683 2-s2.0-84860340270 10.1016/j.cell.2012.03.029
171. Han S., Liang C. P., DeVries-Seimon T., Ranalletta M., Welch C. L., Collins-Fletcher K., Accili D., Tabas I., Tall A. R., Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metabolism 2006 3 4 257 266 2-s2.0-33645567816 10.1016/j.cmet.2006.02.008
172. Tabas I., Tall A., Accili D., The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. Circulation Research 2010 106 1 58 67 2-s2.0-74049093243 10.1161/CIRCRESAHA.109.208488
173. Hulsmans M., van Dooren E., Mathieu C., Holvoet P., Decrease of miR-146b-5p in monocytes during obesity is associated with loss of the anti-inflammatory but not insulin signaling action of adiponectin. PLoS ONE 2012 7 2 e32794 2-s2.0-84857681898 10.1371/journal.pone.0032794
174. Foley N. H., O'Neill L. A., miR-107: a Toll-like receptor-regulated miRNA dysregulated in obesity and type II diabetes. Journal of Leukocyte Biology 2012 92 3 521 527 2-s2.0-84865494840 10.1189/jlb.0312160
175. Hennessy E. J., Sheedy F. J., Santamaria D., Barbacid M., O'Neill L. A. J., Toll-like receptor-4 (TLR4) down-regulates microRNA-107, increasing macrophage adhesion via cyclin-dependent kinase 6. The Journal of Biological Chemistry 2011 286 29 25531 25539 2-s2.0-79960394016 10.1074/jbc.M111.256206
176. Tang X., Muniappan L., Tang G., Özcan S., Identification of glucose-regulated miRNAs from pancreatic β cells reveals a role for miR-30d in insulin transcription. RNA 2009 15 2 287 293 2-s2.0-58249107416 10.1261/rna.1211209
177. Herrera B. M., Lockstone H. E., Taylor J. M., Ria M., Barrett A., Collins S., Kaisaki P., Argoud K., Fernandez C., Travers M. E., Grew J. P., Randall J. C., Gloyn A. L., Gauguier D., McCarthy M. I., Lindgren C. M., Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 2010 53 6 1099 1109 2-s2.0-77952099464 10.1007/s00125-010-1667-2
178. Trajkovski M., Hausser J., Soutschek J., Bhat B., Akin A., Zavolan M., Heim M. H., Stoffel M., MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011 474 7353 649 653 2-s2.0-79959845414 10.1038/nature10112